Month: April 2020

Schibsted’s employee share saving plan (ESSP) continues in 2020 with saving in the Schibsted B-share.Attached to this release is a list of primary insiders that have subscribed to the share saving plan for 2020. The subscribed amount disclosed is the total amount in NOK for 2020. Primary insiders can only change their savings amount once a year. The purchase price and the number of shares will be reported when allocations are made.For more information on the employee share saving plan please refer to the disclosure published 09 April 2014.Oslo, 08 April 2020SCHIBSTED ASAThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentESSP 2020 Primary Insiders Participation

Robust cash position at December 31, 2019 of CHF 31.5 million providing runway through 2021Awarded Eurostars / Innosuisse grant of €4.85 million supporting mGlu7 NAM PTSD programAdditional funding of $1.6 million in 2019 from Indivior to support GABAB PAM addiction programDipraglurant pivotal registration study in PD-LID ready to start dosing patients subject to lifting of restrictions in US associated with the global Covid-19 crisisGeneva, Switzerland, April 8, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its full-year audited results for the year ended December 31, 2019 and provided a corporate update.“We made significant progress in 2019 in advancing our pipeline of innovative in-house discovered...

Pratteln, Switzerland, April 8, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that it has entered into an equity-linked financing arrangement with IRIS (France) in the initial gross amount of up to CHF 12 million over 12 months, with the option to extend by another CHF 12 million over another 12 months. IRIS will receive Santhera shares to be created from the Company’s authorized capital and is expected to sell these shares on the market or in block trades. It remains at the sole discretion of Santhera to suspend or terminate the staggered financing.

Pratteln, Schweiz, 8. April 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt den Abschluss einer aktiengebundenen Finanzierungsvereinbarung mit IRIS (Frankreich) mit anfänglichem Bruttobetrag von bis zu CHF 12 Millionen über 12 Monate und mit der Option auf eine Erhöhung um zusätzliche CHF 12 Millionen über weitere 12 Monate bekannt. IRIS wird aus dem genehmigten Kapital des Unternehmens zu schaffende Santhera-Aktien erhalten und diese erwartungsgemäss am Kapitalmarkt oder im Blockhandel verkaufen. Es liegt im alleinigen Ermessen von Santhera, die gestaffelte Finanzierung auszusetzen oder zu beenden.Die aktiengebundene Finanzierung wurde eingerichtet, um zusätzliche Liquidität zur Unterstützung der laufenden Zulassungs- und Entwicklungsprogramme des Unternehmens in einer Gesamthöhe von bis zu CHF 24 Millionen über einen Zeitraum von bis...

Press ReleaseAntwerp (Berchem), 8 April 2020, 07h00 CETThe shareholders are hereby invited to attend the annual and extraordinary shareholders’ meeting of the Company which shall take place at registered office of the Company, at Uitbreidingstraat 72, 2600 Antwerp, Belgium, on Friday 8 May 2020 at 10:00 am, with following agenda and proposed resolutions:Information note:The board of directors closely monitors the evolution of the Covid-19 pandemic and the sanitary regulations issued by the Belgian authorities in this regard and continues to evaluate the impact thereof on the organisation of the shareholders’ meetings.The board of directors has at this stage decided not to postpone the shareholders’ meetings. The Company will however take appropriate measures to ensure that the shareholders’ meetings take place in compliance with the sanitary...

PersberichtAntwerpen (Berchem), 8 april 2020, 07h00 CET                                        De aandeelhouders worden hierbij uitgenodigd om deel te nemen aan de gewone en de buitengewone algemene vergadering van de Vennootschap die zal plaatsvinden op de zetel van de Vennootschap te Uitbreidingstraat 72, 2600 Antwerpen, België, op vrijdag 8 mei 2020 om 10.00 uur, met de hierna vermelde agenda en voorstellen tot besluit.Informatieve nota:De raad van bestuur volgt de evolutie van de Covid-19-pandemie en de sanitaire maatregelen die de Belgische autoriteiten in dit verband uitvaardigen op de voet en blijft de impact ervan op de organisatie van algemene vergaderingen evalueren.De raad van bestuur heeft voorlopig besloten de algemene vergaderingen niet uit te stellen. De Vennootschap zal echter passende maatregelen nemen om ervoor te zorgen...

VANCOUVER, British Columbia, April 08, 2020 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer for both domestic and European export sales, is pleased to announce that further to its news release on March 24, 2020, it has acquired a 50% interest in a joint venture called Cannation Ltd. for a phased partnership of two near-term farm operations located in the Hefer Valley region of Israel.Cannation has an offtake agreement with Focus Medical Herbs Ltd. (“Focus Medical”), a licensed medical cannabis producer in Israel, for a three-year definitive supply agreement with Cannation for approximately 2,600kg of medical cannabis per year, for a total of up to 7,800kg of...

ANN ARBOR, Mich., April 07, 2020 (GLOBE NEWSWIRE) — Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of its previously announced public offering of 33,333,334 common shares and warrants to purchase up to 16,666,667 common shares. The securities are being sold in a fixed combination consisting of one common share and 0.5 of a warrant at a combined public offering price of $0.12 per share and accompanying warrant. Each whole warrant will be exercisable for one common share. The gross proceeds to Zomedica from this offering are expected to be approximately $4.0 million, before deducting placement agent fees and other estimated offering expenses, and excluding the exercise of any warrants. All of the common shares and warrants in the offering...

CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it has raised gross proceeds of approximately $65 million through its At-the-Market (ATM) facility with participation based on interest received from Avoro Capital Advisors LLC, Bain Capital Life Sciences, Consonance Capital Investors and David Mott, Mersana’s Chairman of the Board. The Company sold approximately 8.9 million shares of the Company’s common stock at a purchase price of $5.59 and 2.0 million shares at the closing price of $7.74, in each case the market price at the time of sale. Cowen is acting as the sales agent for the ATM...

MONTREAL, April 07, 2020 (GLOBE NEWSWIRE) — Laurentian Bank of Canada (TSX: LB) announces that the candidates nominated as directors of Laurentian Bank of Canada (the “Bank”), as identified in the Management Proxy Circular dated February 7, 2020, have all been elected. The election took place earlier today, during the Bank’s Annual Meeting of Shareholders. The detailed results of the vote are set out below.The 10 candidates nominated by management were elected as directors of the Bank:Voting results on all matters voted on at the Annual Meeting of Shareholders of the Bank will be published shortly on https://lbcfg.ca/, and filed on SEDAR.About Laurentian Bank Financial GroupFounded in 1846, Laurentian Bank Financial Group is a diversified financial services provider whose mission is to help its customers improve their financial...